Effectiveness of 3% Boric Acid in 70% Alcohol Versus 1% Clotrimazole Solution in Otomycosis Patients
Launched by KHON KAEN HOSPITAL · Mar 3, 2012
Trial Information
Current as of July 21, 2025
Completed
Keywords
ClinConnect Summary
The hypothesis has been formulated by H0 and Ha. H0 = 1% clotrimazole solution has clinical effectiveness not different from 3% boric acid in 70% alcohol for the treatment of otomycosis.
Ha = 1% clotrimazole solution has more clinical effectiveness than 3% boric acid in 70% alcohol for the treatment of otomycosis.
Inclusion criteria:
* Symptomatic otomycosis, age more than 7 year.
* Microscopic finding revealed fungus
* KOH smear positive for fungus
Exclusion criteria:
* Pregnancy
* Tympanic membrane perforation and post mastoid surgery
* Co-infection of ear e.g. severe otitis externa,...
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • Symptomatic otomycosis, age more than 7 year.
- • Microscopic finding revealed fungus
- • KOH smear positive for fungus
- Exclusion Criteria:
- • Pregnancy
- • Tympanic membrane perforation and post mastoid surgery
- • Co-infection of ear e.g. severe otitis externa, severe myringitis which are needed other medications
- • Previous using topical antibiotic / steroid within 2weeks.
- • During usage of systemic antifungal drug
- • Allergic to 3% boric acid in70% alcohol or 1% clotrimazole solution.
- • Those who can not come to follow up after one week of the treatment
About Khon Kaen Hospital
Khon Kaen Hospital is a leading healthcare institution in Thailand, renowned for its commitment to advancing medical research and improving patient outcomes. As a prominent clinical trial sponsor, the hospital is dedicated to conducting innovative studies that adhere to the highest ethical standards and regulatory guidelines. With a multidisciplinary team of experienced healthcare professionals, Khon Kaen Hospital fosters collaboration and utilizes cutting-edge technology to facilitate clinical trials across various medical fields. The institution's focus on patient safety and data integrity ensures that its research contributes significantly to the global medical community and enhances the quality of care provided to its patients.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Khonkaen, , Thailand
Patients applied
Trial Officials
Sarisa Romsaithong, M.D.
Principal Investigator
Unaffiliate
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials